Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Zealand Pharma A/S: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Zealand Pharma A/S
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Zealand Pharma A/S
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company has insufficient levels of profitability.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Rating Financials

Zealand Pharma A/S SectorDenmark
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability-
EBITDA Margin-
EBIT Margin-
Net Margin-
Capital Efficiency
ROA
ROCE-
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth-
Long Term balance sheet growth-
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Zealand Pharma A/S SectorDenmark
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield-
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Zealand Pharma A/S SectorDenmark
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Zealand Pharma A/S SectorDenmark
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Zealand Pharma A/S SectorDenmark
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
5.44B
BBB
54.11B
AA
42.02B -
BBB
- -
39.6B
AAA
22.8B - - - -
19.5B
AA
17.76B
AAA
14.73B
B
-
13.55B - - - -
13.14B -
A
- -
Average 24.26B
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. Ratings Zealand Pharma A/S